Pathology

Empowering Innovation: StatLab Welcomes Scientific Device Laboratory Into Family

Retrieved on: 
Giovedì, Aprile 25, 2024
Other Manufacturing, Research, Medical Devices, Medical Supplies, Hospitals, Chemicals, Plastics, Manufacturing, Biotechnology, Health, Science, Hospital, Acquisition, Multimedia, Microbiology, Pathology, Associate, SDL, Original equipment manufacturer

StatLab Medical Products (“StatLab”), a leading developer and manufacturer of medical diagnostic supplies and equipment, today announced the acquisition of Scientific Device Laboratory (“SDL”), a Chicago-based manufacturer of printed diagnostic slides and a variety of consumables and kits for the anatomic pathology and microbiology markets.

Key Points: 
  • StatLab Medical Products (“StatLab”), a leading developer and manufacturer of medical diagnostic supplies and equipment, today announced the acquisition of Scientific Device Laboratory (“SDL”), a Chicago-based manufacturer of printed diagnostic slides and a variety of consumables and kits for the anatomic pathology and microbiology markets.
  • The addition of SDL to the StatLab family of businesses expands customer reach for both entities and provides a new U.S. research and development hub for the broader StatLab organization.
  • View the full release here: https://www.businesswire.com/news/home/20240425390116/en/
    Scientific Device Laboratory manufactures custom printed diagnostic slides, among other microbiology and anatomic pathology consumables and kits.
  • Arakelian and Associates LLC served as exclusive financial advisor to Scientific Device Laboratory on this transaction.

XiFin to Highlight Impact of FDA Regulations, Other Disruptive Forces Facing Hospitals, Independent Labs, and Pathology Practices at 29th Annual Executive War College

Retrieved on: 
Martedì, Aprile 23, 2024
General Health, Health, FDA, Artificial Intelligence, Data Management, Hospitals, Health Technology, Technology, Policy, White paper, Payment, Intelligence, Molecular diagnostics, Environment, Pathology, RCM, Region, Specialty, Medicare, Multimedia, Associate, Management

Leveraging insights on big data gleaned from its experienced team of industry leading executives and award-winning platform, XiFin leaders plan to drive strategic, financial, and operational discussions.

Key Points: 
  • Leveraging insights on big data gleaned from its experienced team of industry leading executives and award-winning platform, XiFin leaders plan to drive strategic, financial, and operational discussions.
  • From top left to right, Diana Richard, Stephanie Denham, Jeff Carmichael, Sandra Greefkes, Heather Agostinelli, and Clarisa Blattner.
  • (Photo: Business Wire)
    XiFin Executive Chair and CEO Lâle White will deliver a keynote focusing on the new regulations and market forces that will impact the diagnostic industry.
  • In addition, XiFin will share its new White Paper “Guide to AI-Enabled Revenue Cycle Management for Molecular Diagnostics and Pathology Practices” with all attendees.

Clarapath Forms Strategic Collaboration with Mayo Clinic to Advance Pathology Tissue Processing

Retrieved on: 
Martedì, Aprile 23, 2024
Technology, Other Health, Health, Oncology, Robotics, Health Technology, Medical Devices, Software, Artificial Intelligence, Hardware, Electronic Design Automation, Education, Mayo Clinic, Laboratory, Safety, Anatomical pathology, Medical laboratory, Research, Pathology, Intelligence, Automation, Patient, Histology, Organization, Medical imaging

Clarapath , a medical robotics company transforming the way pathology laboratories process tissue, announced it has entered into a strategic collaboration with Mayo Clinic to propel a new era of laboratory automation.

Key Points: 
  • Clarapath , a medical robotics company transforming the way pathology laboratories process tissue, announced it has entered into a strategic collaboration with Mayo Clinic to propel a new era of laboratory automation.
  • The strategic collaboration combines Clarapath’s innovative tissue solution and domain experts with the clinical insights and expertise of Mayo Clinic.
  • “We are thrilled to collaborate with Mayo Clinic to advance the modernization of anatomic pathology,” said Eric Feinstein, CEO of Clarapath.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

Anne Arundel Dermatology Adds Intelligent Scheduling Capabilities to Improve Patient Experience

Retrieved on: 
Martedì, Aprile 23, 2024
Data Management, Health, Technology, Practice Management, Health Technology, Software, General Health, Dermatology, Partnership, Patient, Research, Pathology, Organization, Nursing

Anne Arundel Dermatology (AADerm), a leading provider of medical, surgical, pathology, research and aesthetic dermatological services, announced today that it will add new intelligent patient scheduling tools, expanding its existing partnership with Relatient , a leading patient scheduling platform.

Key Points: 
  • Anne Arundel Dermatology (AADerm), a leading provider of medical, surgical, pathology, research and aesthetic dermatological services, announced today that it will add new intelligent patient scheduling tools, expanding its existing partnership with Relatient , a leading patient scheduling platform.
  • We pride ourselves on attentiveness to both clinical and interpersonal details that enable us to deliver the best care,” said Vincent Bradley, CEO of Anne Arundel Dermatology.
  • This, paired with Relatient's proven track record in patient scheduling, made it a no-brainer to expand our work.
  • We’re thrilled to help Anne Arundel lead the way on these key initiatives.”

REPLY: Value Based Medicine Is Born, the Platform Created by Laife Reply for IEO That Makes Patient Care Increasingly Personalised and Appropriate

Retrieved on: 
Lunedì, Aprile 22, 2024
Technology, Medical Devices, Health Technology, Software, Internet, Health, General Health, Data Management, Artificial Intelligence, Society, Big data, IEO, Digital therapeutics, Health communication, Probability, AI, Elective surgery, Breast, CDP, Insurance, Research, STAR, Pathology, Science, Cloud computing, Intelligence, Drug discovery, Digital, Natural language, Digital health, VBM, Machine learning, Patient, European Institute, Medical imaging, Tangibility, Value, Natural language processing, EXM, Quality of life

The project by Laife Reply and IEO embodies the principles of value-based medicine.

Key Points: 
  • The project by Laife Reply and IEO embodies the principles of value-based medicine.
  • It implements, in a software platform, methods for measuring the improvement of patient care outcomes.
  • The AI tools adopted allow dynamically defining predictive models for each patient, effectively creating a personalised value measurement pathway.
  • Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media.

Executive War College to Address, Clinical Laboratories’ and Genetic Testing Firms’ Perfect Storm, involving FDA’s Proposed LDT Rule, Payers Requiring Z-Codes on Genetic Test Claims, and Revisions to CLIA Regulations

Retrieved on: 
Venerdì, Aprile 19, 2024
FDA, Health Technology, Publishing, Healthcare Reform, Communications, General Health, Medical Devices, Public Policy, Government, Genetics, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Dark, Storm, Organization, COLA, Leica Biosystems, Laboratory, Food, CDC, Cleveland Clinic, DLS, MD, Clinical Laboratory, Doctor of Philosophy, ISO, Pathology, Artificial intelligence, History, Genetic testing, ARUP Laboratories, CLIA, Marie Cassidy, Medical device, College, Multimedia, French Quarter, Division, IVD, Darkness

One is the Food and Drug Administration’s (FDA) proposed rule https://www.fda.gov/news-events/press-announcements/fda-proposes-rule-ai... to regulate laboratory developed tests (LDTs).

Key Points: 

CAP Publishes Guideline for PD-L1 Testing of Patients with Lung Cancer

Retrieved on: 
Martedì, Aprile 16, 2024
University, Education, Health, General Health, Oncology, Other Science, Research, Science, Other Education, Clinical Trials, Continuing, Patient, Lung cancer, Programmed cell death, Laboratory, Survival, Immunotherapy, Medical laboratory, Pathology, IHC, PD-1, Guideline, Apoptosis, PD-L1, International Association, TMB, AMP, College, CAP, Biomarker, Immune system, Antibody, Running, NSCLC, Capitol, PPS

“Many lung cancer patients may benefit from therapies that can harness the immune system, including anti-PD-1 or PD-L1 therapies.

Key Points: 
  • “Many lung cancer patients may benefit from therapies that can harness the immune system, including anti-PD-1 or PD-L1 therapies.
  • “This guideline is intended to provide an overview of the clinical rationale for the use of PD-L1 and tumor mutational burden (TMB) testing for patients with non-small lung cancer.
  • With six recommendations, the guideline provides data and details regarding the efficacy and utility of PD-L1 testing of patients with lung cancer.
  • Current tools, resources, and information for the PD-L1 Testing of Patients with Lung Cancer Guideline can be found on the guideline webpage on cap.org.

Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing

Retrieved on: 
Martedì, Aprile 16, 2024
Research, Animal Welfare, Medical Devices, Public Policy, Government, Biotechnology, Health, Pharmaceutical, General Health, Science, Corporation, Safety, Policy, Valo, AI, Animal, Pathology, Logica, Patient safety, AMAP, Patient, The three Rs, Multimedia, Non-governmental organization, Drug development, CRL, Drug discovery, Pharmaceutical industry

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing.
  • This investment spans a portfolio of technology innovations, partnerships, and advocacy efforts to reduce the use of animal testing.
  • View the full release here: https://www.businesswire.com/news/home/20240416134140/en/
    Understanding that stakeholders across drug development must collaborate to pursue these advances, AMAP is comprised of Charles River experts in animal welfare, science, technology, operations, and advocacy.
  • AMAP focus is on three key pillars:
    Products & Services: Charles River is committed to innovating and expanding its portfolio to include more animal alternatives.

Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology

Retrieved on: 
Giovedì, Aprile 11, 2024
Data Management, Biotechnology, Technology, Health, General Health, Pharmaceutical, Medical Devices, Research, Software, Artificial Intelligence, Science, Safety, Tissue, Doctor of Philosophy, Pathology, Marie Cassidy, Charles River Laboratories, MBA, Drug development, CRL, Drug discovery, WSI, Organization

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology AI.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology AI.
  • In experimental and toxicologic pathology in particular, traditional light microscopic pathology methods can fall short of maintaining consistency and efficiency in analyzing histopathology data.
  • By augmenting evaluations with decision support technology, toxicologic pathologists have access to simple, visual tools to facilitate efficiency, consistency, and accuracy in their work.
  • Developed through a research collaboration between Charles River and Deciphex, Patholytix Foresight incorporates organ-based lesion classifiers created from an extensive data warehouse.

GE HealthCare to feature Mobile Mammography Screening Truck along with Latest AI Platform as part of SBI2024 Breast Cancer Imaging Showcase

Retrieved on: 
Venerdì, Aprile 12, 2024
Other Consumer, Women, Other Health, Photography, Radiology, Oncology, Software, Artificial Intelligence, Medical Devices, Hospitals, Electronic Design Automation, Consumer, Technology, General Health, Biotechnology, Health, Apps, Applications, Health Technology, FDA, Cancer, Boston Medical Center, CME, GE HealthCare, Woman, Publication, Malignancy, SBI, Breast cancer, Workplace, Research, Pathology, Artificial intelligence, DBT, CEM, Patient, Biopsy, Diagnosis, Self-assessment, Breast, Medical imaging

GE HealthCare (Nasdaq: GEHC), a leader in breast health technology and diagnostics, will feature its latest breast cancer detection technology during the 2024 Society of Breast Imaging Symposium in Montreal, Canada, April 11-14, 2024.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC), a leader in breast health technology and diagnostics, will feature its latest breast cancer detection technology during the 2024 Society of Breast Imaging Symposium in Montreal, Canada, April 11-14, 2024.
  • This year’s showcase will feature the Mobile Mammography Screening Truck, the recently released MyBreastAI Suite* and Pristina Bright** offering to demonstrate the company’s personalized approach to transforming breast cancer imaging.
  • The truck is equipped with the Senographe Pristina and Invenia ABUS to ensure accurate and efficient screenings.
  • *MyBreastAI suite is a commercial offering that includes GE HealthCare’s Edison Health Services platform, ProFound AI® for DBT, SecondLook for 2D Mammography and PowerLook® Density Assessment.